Dara-PD in the Treatment of Patients With First Relapse of Multiple Myeloma
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorFengYan Jin
About this trial
At present, there is no prospective study on the treatment of first-relapsed multiple myeloma with daratumumab plus pomalidomide and dexamethasone (Dara-Pd). A prospective, multicenter, open, non-interventional, observational clinical study to evaluate the efficacy and safety of Dara-Pd in patients with first relapse multiple myeloma.
Eligibility criteria
Qualifiers
Age 18 years or older, regardless of gender.
Diagnosis of symptomatic multiple myeloma based on the 2014 IMWG diagnostic criteria and the presence of measurable disease
First relapse of multiple myeloma;
Receiving first-line anti-multiple myeloma therapy;
Disqualifiers
Diagnosis of inactive multiple myeloma, including primary amyloidosis, MGUS (monoclonal gammopathy of undetermined significance) or smoldering myeloma.
Relapsed and refractory myeloma：Relapsed and refractory myeloma is defined as disease that is nonresponsive while on salvage therapy, or progresses within 60 days of last therapy in patients who have achieved minimal response (MR) or better at some point previously before then progressing in their disease course；
Primary refractory myeloma：Primary refractory myeloma is defined as disease that is nonresponsive in patients who have never achieved a minimal response or better with any therapy；
Subject has received daratumumab or pomalidomide previously；
Trial design
Treatments tested in this trial
- Not listed
Trial groups
50 Participants
are grouped into 2 trial groupsSponsors and collaborators
FengYan Jin
Lead sponsor
The First Hospital of Jilin University
Sponsor institution
Affiliated Hospital of Hebei University
Collaborator
Second Hospital of Shanxi Medical University
Collaborator
Shandong Cancer Hospital and Institute
Collaborator
First Affiliated Hospital of Jinan University
Collaborator
Sun Yat-Sen University Cancer Center
Collaborator
Source ClinicalTrials.gov